lemma health

Newer treatments for atopic dermatitis (like dupilumab, tralokinumab, lebrikizumab, and JAK inhibitors) are showing better results with fewer side effects compared to older medications. High dose cyclosporine and dupilumab work better than methotrexate and azathioprine. While high-dose upadacitinib was most effective, it had more side effects.

Cyclosporine A was effective in treating severe atopic dermatitis in children, with 64% of patients showing good or excellent response after 4 weeks. Side effects were common but mild, and 20% of patients maintained improvement for more than 6 months after treatment.

Newer treatments for atopic dermatitis (like dupilumab, tralokinumab, lebrikizumab, and JAK inhibitors) are showing better results with fewer side effects compared to older medications. High dose cyclosporine and dupilumab work better than methotrexate and azathioprine. While high-dose upadacitinib was most effective, it had more side effects.

Cyclosporine A was effective in treating severe atopic dermatitis in children, with 64% of patients showing good or excellent response after 4 weeks. Side effects were common but mild, and 20% of patients maintained improvement for more than 6 months after treatment.

Both cyclosporine and methotrexate were effective in treating severe eczema in children and young people. Cyclosporine worked faster, but methotrexate's effects lasted longer after stopping treatment.

This study compared two medications for moderate-to-severe eczema: dupilumab and cyclosporine. Dupilumab showed better results than cyclosporine in reducing eczema severity, both in the short term (12-16 weeks) and longer term (24-30 weeks). About 75-80% of patients on dupilumab had significant improvement compared to 40-56% on cyclosporine.

This study compared how long patients stayed on different medications for atopic dermatitis and why they stopped taking them. Dupilumab had the highest continuation rate, with only one patient stopping treatment. Other medications like cyclosporine, azathioprine, and methotrexate were often stopped due to side effects.

Patients with moderate to severe atopic dermatitis stayed on cyclosporine treatment for about 1 year on average. This duration was longer than in patients with psoriasis, who stayed on the medication for about 4.4 months.

This study looked at 10 years of data on oral immunosuppressive treatments for severe atopic dermatitis in two hospitals. Cyclosporine A was the most commonly used medication (80% of patients), followed by mycophenolate mofetil (31%). Treatment was often stopped due to either the disease being controlled, the medication not working, or side effects.

This real-world study looked at side effects of various medications used to treat atopic dermatitis, including dupilumab and other immunomodulating drugs. The study found some side effects occurred more frequently than expected, particularly eye-related issues and facial redness with dupilumab, and fatigue with methotrexate.

This study looked at 10 years of data on oral immunosuppressive treatments for severe atopic dermatitis in two hospitals. Cyclosporine A was the most commonly used medication (80% of patients), followed by mycophenolate mofetil (31%). Treatment was often stopped due to either the disease being controlled, the medication not working, or side effects.

A patient treated with mycophenolate mofetil (MMF) for atopic dermatitis developed a fungal infection in their esophagus after 22 months of treatment. This is a rare complication that hasn't been reported before with MMF treatment.

A patient with severe atopic dermatitis was treated with mycophenolate mofetil (MMF) and developed lung problems (interstitial lung disease) as a side effect. After stopping MMF and receiving steroid treatment, the patient's lung condition improved.

This real-world study compared the safety of dupilumab to conventional systemic treatments for atopic dermatitis over 5 years. Dupilumab showed fewer side effects related to circulatory, respiratory, and musculoskeletal systems, and infections compared to other treatments. However, it did have a higher risk of eye inflammation (conjunctivitis) compared to some other medications.

This study compared how long patients stayed on different medications for atopic dermatitis and why they stopped taking them. Dupilumab had the highest continuation rate, with only one patient stopping treatment. Other medications like cyclosporine, azathioprine, and methotrexate were often stopped due to side effects.

Newer treatments for atopic dermatitis (like dupilumab, tralokinumab, lebrikizumab, and JAK inhibitors) are showing better results with fewer side effects compared to older medications. High dose cyclosporine and dupilumab work better than methotrexate and azathioprine. While high-dose upadacitinib was most effective, it had more side effects.

This study compared two medications for moderate-to-severe eczema: methotrexate and cyclosporine. While cyclosporine worked better at 8 weeks, increasing the dose of methotrexate led to similar effectiveness by 20 weeks. Cyclosporine had more side effects than methotrexate.

Newer treatments for atopic dermatitis (like dupilumab, tralokinumab, lebrikizumab, and JAK inhibitors) are showing better results with fewer side effects compared to older medications. High dose cyclosporine and dupilumab work better than methotrexate and azathioprine. While high-dose upadacitinib was most effective, it had more side effects.

This study compared two medications for moderate-to-severe eczema: methotrexate and cyclosporine. While cyclosporine worked better at 8 weeks, increasing the dose of methotrexate led to similar effectiveness by 20 weeks. Cyclosporine had more side effects than methotrexate.

This study compared how long children with severe eczema stayed on different medications (dupilumab, methotrexate, and cyclosporine). Dupilumab showed the best long-term results, with 84% of patients still using it after 1 year, compared to 61% for methotrexate and 44% for cyclosporine. The main reasons patients stopped treatments were because they weren't working well enough or because of side effects.

Newer treatments for atopic dermatitis (like dupilumab, tralokinumab, lebrikizumab, and JAK inhibitors) are showing better results with fewer side effects compared to older medications. High dose cyclosporine and dupilumab work better than methotrexate and azathioprine. While high-dose upadacitinib was most effective, it had more side effects.

Both cyclosporine and methotrexate were effective in treating severe eczema in children and young people. Cyclosporine worked faster, but methotrexate's effects lasted longer after stopping treatment.

Baricitinib 4mg combined with topical steroids helped improve moderate-to-severe atopic dermatitis symptoms in adults after 16 weeks of treatment. About 48% of patients on 4mg baricitinib achieved a 75% improvement in their eczema severity score (EASI-75), compared to 23% on placebo. The medication also helped reduce itch quickly, with improvements seen as early as 2 days after starting treatment.

Baricitinib, whether used alone or with topical steroids, quickly improved all four main signs of eczema (excoriation, swelling/bumps, redness, and skin thickening). The medication worked particularly well for reducing scratching damage, with improvements seen as early as the first week of treatment.

Baricitinib is effective in treating moderate-to-severe atopic dermatitis in adults. Clinical trials showed that it can significantly improve skin clearance and reduce itch, with about 30-40% of patients achieving clear or almost clear skin after 16 weeks of treatment.

This study looked at what happens when patients who responded well to baricitinib either continued their dose, reduced their dose, or stopped treatment completely. Most patients who reduced their dose maintained improvement in their eczema, and those who lost improvement usually got better again when restarting their original dose.

Baricitinib combined with topical steroids showed long-term effectiveness in treating moderate-to-severe eczema for up to 68 weeks. About 40-60% of patients saw significant improvement in their eczema symptoms, and around 40-50% experienced meaningful itch reduction.

Baricitinib 4mg combined with topical steroids helped improve moderate-to-severe atopic dermatitis symptoms in adults after 16 weeks of treatment. About 48% of patients on 4mg baricitinib achieved a 75% improvement in their eczema severity score (EASI-75), compared to 23% on placebo. The medication also helped reduce itch quickly, with improvements seen as early as 2 days after starting treatment.

Baricitinib combined with topical steroids was effective in treating moderate-to-severe eczema in patients who couldn't use or didn't respond to ciclosporin. After 16 weeks, 32% of patients on the highest dose (4mg) had their eczema improve by 75% or more, compared to 17% on placebo, and these improvements lasted for up to one year.

Baricitinib showed some effectiveness in treating difficult-to-treat eczema patients, including those who didn't respond to dupilumab. However, about 43% of patients stopped treatment due to either lack of effectiveness or side effects. The most common side effects were nausea, urinary tract infections, and herpes simplex infections.

Newer treatments for atopic dermatitis (like dupilumab, tralokinumab, lebrikizumab, and JAK inhibitors) are showing better results with fewer side effects compared to older medications. High dose cyclosporine and dupilumab work better than methotrexate and azathioprine. While high-dose upadacitinib was most effective, it had more side effects.

Newer treatments for atopic dermatitis (like dupilumab, tralokinumab, lebrikizumab, and JAK inhibitors) are showing better results with fewer side effects compared to older medications. High dose cyclosporine and dupilumab work better than methotrexate and azathioprine. While high-dose upadacitinib was most effective, it had more side effects.

Newer treatments for atopic dermatitis (like dupilumab, tralokinumab, lebrikizumab, and JAK inhibitors) are showing better results with fewer side effects compared to older medications. High dose cyclosporine and dupilumab work better than methotrexate and azathioprine. While high-dose upadacitinib was most effective, it had more side effects.

This study compared how long patients stayed on different medications for atopic dermatitis and why they stopped taking them. Dupilumab had the highest continuation rate, with only one patient stopping treatment. Other medications like cyclosporine, azathioprine, and methotrexate were often stopped due to side effects.

This study compared how long patients stayed on different medications for atopic dermatitis and why they stopped taking them. Dupilumab had the highest continuation rate, with only one patient stopping treatment. Other medications like cyclosporine, azathioprine, and methotrexate were often stopped due to side effects.

This study looked at 10 years of data on oral immunosuppressive treatments for severe atopic dermatitis in two hospitals. Cyclosporine A was the most commonly used medication (80% of patients), followed by mycophenolate mofetil (31%). Treatment was often stopped due to either the disease being controlled, the medication not working, or side effects.